National Guideline Clearinghouse | Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer.
National Institute for Health and Care Excellence (NICE)
December 2, 2013
Guideline Title
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer.
Bibliographic Source(s)
| National Institute for Health and Care Excellence (NICE). Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer. London (UK): National Institute for Health and Care Excellence (NICE); 2013 May. 44 p. (Technology appraisal guidance; no. 284). |
Guideline Status
This is the current release of the guideline.
No hay comentarios:
Publicar un comentario